Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
-
Published:2022-03
Issue:
Volume:6
Page:3-5
-
ISSN:2666-3287
-
Container-title:JAAD International
-
language:en
-
Short-container-title:JAAD International
Author:
Lytvyn YuliyaORCID,
Mufti Asfandyar,
Zaaroura HibaORCID,
Sachdeva Muskaan,
Lu Justin D.,
Rankin Brian D.,
Prajapati Vimal H.,
Vender RonaldORCID,
Yeung Jensen
Reference5 articles.
1. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials;Gordon;Lancet,2018
2. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial;Warren;Br J Dermatol,2021
3. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial;Blauvelt;JAMA Dermatol,2020
4. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic;Hansel;J Eur Acad Dermatol Venereol,2021
5. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis;Egeberg;J Am Acad Dermatol,2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献